Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

827 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
Cardona AF, Ordóñez-Reyes C, Ruiz-Patiño A, Garcia-Robledo JE, Barron LZ, Recondo G, Rojas L, Corrales L, Martín C, Barrón F, Sotelo C, Rodríguez J, Ricaurte L, Rolfo C, Ávila J, Mayorga D, Archila P, Otero J, Mas L, Bermudez M, Gamez T, Carranza H, Vargas C, Rosell R, Arrieta O. Cardona AF, et al. Among authors: rosell r. JCO Precis Oncol. 2021 Nov;5:839-848. doi: 10.1200/PO.20.00404. JCO Precis Oncol. 2021. PMID: 34994616
Ifosfamide in non-small-cell lung cancer.
Rosell R, Martin C, Balaña C. Rosell R, et al. Ann Oncol. 1999;10 Suppl 5:S25-8. doi: 10.1093/annonc/10.suppl_5.s26. Ann Oncol. 1999. PMID: 10582135 Free article. Review.
BRCA1: a new genomic marker for non-small-cell lung cancer.
Reguart N, Cardona AF, Carrasco E, Gomez P, Taron M, Rosell R. Reguart N, et al. Among authors: rosell r. Clin Lung Cancer. 2008 Nov;9(6):331-9. doi: 10.3816/CLC.2008.n.048. Clin Lung Cancer. 2008. PMID: 19073515 Review.
Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Rosell R, et al. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692684 Free article.
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R. Salazar F, et al. Among authors: rosell r. Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11. Lung Cancer. 2011. PMID: 20705357
827 results